Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients

Author： Huillard Olivier Boissier Emilie Blanchet Benoit Thomas-Schoemann Audrey Cessot Anatole Boudou-Rouquette Pascaline Durand Jean-Philippe Coriat Romain Giroux Julie Alexandre Jerome Vidal Michel Goldwasser Francois

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.13, Iss.5, 2014-05, pp. : 663-673

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Sorafenib for the treatment of renal cancer

By Strumberg Dirk

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 3, 2012-02 ,pp. : 407-419

Informa Healthcare

Access to resources Recommend Favorite

A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors

By Heath Elisabeth

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1566-1574

Springer Publishing Company

Access to resources Recommend Favorite

Drug safety evaluation of zonisamide for the treatment of epilepsy

By Zaccara Gaetano Tramacere Luciana Cincotta Massimo

Expert Opinion on Drug Safety, Vol. 10, Iss. 4, 2011-07 ,pp. : 623-631

Informa Healthcare

Access to resources Recommend Favorite

Drug safety evaluation of vemurafenib in the treatment of melanoma

By Tsai Kenneth Y Nowroozi Sasan Kim Kevin B

Expert Opinion on Drug Safety, Vol. 12, Iss. 5, 2013-09 ,pp. : 767-775

Informa Healthcare

Access to resources Recommend Favorite

Drug safety evaluation of naltrexone/bupropion for the treatment of obesity

By Verpeut Jessica L Bello Nicholas T

Expert Opinion on Drug Safety, Vol. 13, Iss. 6, 2014-06 ,pp. : 831-841

Informa Healthcare

Access to resources Recommend Favorite